Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

NanoViricides, Inc Therapeutic Pipeline Market Review, H2 2016

Tuesday, October 11, 2016 22:05
% of readers think this story is Fact. Add your two cents.

(Before It's News)


 ‘NanoViricides, Inc. – Product Pipeline Review – 2016’, provides an overview of the NanoViricides, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NanoViricides, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Make an enquiry before buying this Report @    



Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @


- The report provides a snapshot of the pipeline therapeutic landscape of NanoViricides, Inc.
- The report provides overview of NanoViricides, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses NanoViricides, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features NanoViricides, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate NanoViricides, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for NanoViricides, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NanoViricides, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Buy this report @


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
NanoViricides, Inc. Snapshot 6
NanoViricides, Inc. Overview 6
Key Information 6
Key Facts 6
NanoViricides, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
NanoViricides, Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
NanoViricides, Inc. – Pipeline Products Glance 12
NanoViricides, Inc. – Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
NanoViricides, Inc. – Drug Profiles 14
ADIFBase-I 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
DengueCide 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
EKCCide-I 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Herpecide 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
HIVCide-I 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
HIVCide-II 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NVINF-1 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NVINF-2 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RabiCide-I 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule for Cold Sores 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule for Ebola and Marburg Infections 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule for Genital Herpes 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Shingles 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NanoViricides, Inc. – Pipeline Analysis 31
NanoViricides, Inc. – Pipeline Products by Target 31
NanoViricides, Inc. – Pipeline Products by Route of Administration 32
NanoViricides, Inc. – Pipeline Products by Molecule Type 33
NanoViricides, Inc. – Pipeline Products by Mechanism of Action 34
NanoViricides, Inc. – Recent Pipeline Updates 35
NanoViricides, Inc. – Dormant Projects 42
NanoViricides, Inc. – Discontinued Pipeline Products 43
Discontinued Pipeline Product Profiles 43
AviFluCide-I 43
FluCideHP-I 43
NanoViricides, Inc. – Locations And Subsidiaries 44
Head Office 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

Complete report details @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.